Family Medicine

Problems using inhalers correctly is an ongoing issue for both pediatric and adult patients.

An expert in obesity medicine discusses how contracting COVID-19 helped guide her practice.

In a new study presented at ERS 2020, Dr. Mark Levy discusses how a digital inhaler reduces the amount of people who use their inhaler incorrectly.

Countries, including the USA, have shown a stagnation or a small increase of deaths linked to NCDs.

The risk of cardiovascular hospitalizations was associated with increasing PM10 at lag 0.

Early associations from baseline to follow-up go away over time.

Investigators report on a post-hoc analysis of the EMPA-REG OUTCOME trial that assesses the efficacy of the SGLT-2 inhibitor in patients with obstructive sleep apnea.

These guidelines set by ESC and EAS 2019 established treatment goals for LDL-C, non-HDL-C, and Apo-B in patients at high risk for cardiovascular disease.

The new equation model has shown to be more accurate than the Framingham Lifetime Risk equation and Pooled Cohort Equation.

New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.

According to late breaking data, younger women exhibit a decreased risk for heart attack mortality due to estrogen’s protective effect

This underscores a need to reinvent cities and address environmental risk factors that are associated with increased risk for cardiovascular diseases.

Studies have shown that heat-related cardiovascular events have increased over recent years.

New cohort data shows that at least 40% of COVID-19 positive patients had CV risk factors, such as diabetes and hypertension.

Investigators did note that belief in statin use was weaker in patients with confirmed statin associated muscle symptoms when compared with non-SAMS patients.

Accurately assessing lifetime risk in patients with developing atherosclerosis may help reduce CV disease risk earlier in life.

The CLEAR Harmony open-label extension study reports on the long-term effects of BA treatment for hypercholesterolemia.

The new findings break ground on placebo-controlled assessment of the PCSK9 inhibitor for the pediatric population.

Up to 91% patients who received maximum dosage of the drug achieved a triglyceride level of <150 mg/dL, according to new data presented at ESC 2020.

A look at how asymptomatic AFib is being combatted by consumer devices and embraced, large-scale population research.

Daniel Gaudet, MD, PhD, discusses what's next in clinical pursuits of the greatly underdiagnosed hereditary cardiovascular disease.

Investigators simulated baseline CV risk and predicted potential risk reduction among a cohort of evolocumab users across Europe.

A new model using proteomic data from individuals at age 12 could help predict psychotic experiences at age 18.

A podcast interview with the president of American Society of Preventive Cardiology, on the eve of the ESC 2020 Congress.

Youth with repeat concussion have worse outcomes and more delays returning to normal life.